1. Home
  2. GRF vs PRPO Comparison

GRF vs PRPO Comparison

Compare GRF & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.40

Market Cap

39.9M

Sector

Finance

ML Signal

N/A

Logo Precipio Inc.

PRPO

Precipio Inc.

N/A

Current Price

$29.70

Market Cap

42.0M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
GRF
PRPO
Founded
1989
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
42.0M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
GRF
PRPO
Price
$10.40
$29.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.8K
104.8K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
92.15
EPS
1.16
N/A
Revenue
N/A
$24,049,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.97
N/A
Revenue Growth
N/A
29.77
52 Week Low
$9.60
$14.04
52 Week High
$11.85
$33.63

Technical Indicators

Market Signals
Indicator
GRF
PRPO
Relative Strength Index (RSI) 51.16 75.23
Support Level $9.77 $22.25
Resistance Level $10.58 $33.63
Average True Range (ATR) 0.15 1.92
MACD -0.01 0.82
Stochastic Oscillator 45.65 100.00

Price Performance

Historical Comparison
GRF
PRPO

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About PRPO Precipio Inc.

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

Share on Social Networks: